Comparative Pharmacology
Head-to-head clinical analysis: LEVEMIR INNOLET versus LEVEMIR PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVEMIR INNOLET versus LEVEMIR PENFILL.
LEVEMIR INNOLET vs LEVEMIR PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin detemir is a long-acting recombinant human insulin analog. It binds to insulin receptors, activating tyrosine kinase signaling, which promotes cellular glucose uptake, inhibits hepatic gluconeogenesis, and suppresses lipolysis and proteolysis.
Insulin detemir is a long-acting insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake in peripheral tissues (muscle, adipose) and inhibit hepatic glucose production. The addition of a fatty acid chain (myristic acid) to the lysine at position B29 allows reversible binding to albumin, prolonging its duration of action.
0.2 units/kg subcutaneously once daily in the evening or twice daily (morning and evening) when used as basal insulin; titrate to target fasting glucose. For insulin-naive patients with type 2 diabetes, start at 10 units once daily in the evening. Dose adjustment of 1-4 units per day based on blood glucose monitoring.
Subcutaneous injection, starting dose 0.2–0.3 units/kg once daily, titrated to target glucose. Type 1 diabetes: typically 0.3–0.5 units/kg/day. Type 2 diabetes: 10 units once daily, adjusted based on blood glucose.
None Documented
None Documented
Terminal elimination half-life is 13–14 hours after subcutaneous administration, providing a flat, protracted pharmacokinetic profile suitable for once-daily dosing.
Terminal half-life: approximately 13-14 hours (range 12-18 hours) after subcutaneous administration in patients with type 1 diabetes, reflecting prolonged absorption from the injection site. The long half-life supports once-daily dosing.
Hepatic metabolism (deamidation at B30 and deacetylation at B29) and subsequent renal excretion; ~30% of dose excreted unchanged in urine.
Renal: negligible; metabolized by proteolytic degradation, primarily in the liver and kidneys; <1% excreted unchanged in urine. Fecal: minor.
Category C
Category C
Antidiabetic (Long-Acting Insulin)
Antidiabetic (Long-Acting Insulin)